We hereby submit financial Results (standalone & Consolidated) financial results for the quarter ended 30.06.2025 along with Limited Review Report of Auditors thereon. Kindly take the same ....
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ambalal Sarabhai Enterprises reported consolidated revenue from operations of Rs. 4,033.88 lakhs in Q1 FY26, marginally lower than Rs. 4,069.66 lakhs in Q1 FY25. However, total income rose to Rs. 4,869.69 lakhs from Rs. 4,200.91 lakhs, helped by a sharp jump in other income to Rs. 835.81 lakhs (from Rs. 230.25 lakhs), of which Rs. 664.64 lakhs came from a one-time 'provision no longer required'. Net profit surged to Rs. 822.35 lakhs versus Rs. 34.71 lakhs a year ago, with EPS of Rs. 1.07 against Rs. 0.05. On the segment side, Pharmaceuticals revenue grew to Rs. 2,546.42 lakhs (from Rs. 2,326.54 lakhs) while Electronics revenue fell to Rs. 1,487.46 lakhs (from Rs. 1,743.12 lakhs). The Board also constituted a Pharma Committee to oversee the pharmaceutical business. Statutory auditors issued an unqualified limited review report.
Headline profit growth looks dramatic, but a large chunk is a non-recurring provision reversal, so the underlying operating performance is more modest. Investors should watch whether the pharma segment's improved profitability sustains in coming quarters; short-term stock reaction may be positive on the numbers but the quality of earnings is mixed.